Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Clinical trial NCT05465954 · RECRUITING

Trial details

NCT number: NCT05465954
Sponsor: Mayo Clinic
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

High Grade Astrocytic Tumor Recurrent Glioblastoma, IDH-Wildtype Recurrent Gliosarcoma

Start date: 2023-01-24
Primary completion: 2027-10-15
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.